Inside the GLP-1 Study for Long COVID, with lead scientist Dr Julia Vogel, Long Covid, MD Pod, Ep 61 скачать в хорошем качестве

Inside the GLP-1 Study for Long COVID, with lead scientist Dr Julia Vogel, Long Covid, MD Pod, Ep 61

Dr Khan interviews Dr. Julia Moore-Vogel, Scripps Researcher and one of the Principal Investigators on the LoCITT-T study. The study uses tirzepatide to treat moderate to severe long Covid, and is actively enrolling participants. Watch to learn all the important details: the study's design, eligibility criteria, and the potential benefits of the drug. Dr Vogel shares her personal experience with long COVID and how it has influenced her work. The conversation also covers the importance of making clinical trials accessible to those with disabilities and the innovative use of wearable technology in the study. Resources: Long COVID Treatment Trial-Tirzepatide (LoCITT-T): https://www.longcovid.scripps.edu Fatigue Severity Scale: https://www.med.upenn.edu/cbti/assets... FUN-CAP 27: https://batemanhornecenter.org/wp-con... DSQ-COVID: https://www.researchgate.net/publicat... Eric Topol, MD Ground Truths: https://erictopol.substack.com/ All of Us Research Hub: https://www.researchallofus.org/ Chapters 00:00 Introduction to Julia Moore Vogel and Her Work 01:28 Why GLP Drugs Could Work 04:13 The LoCCIT-T Study 07:18 Study Design and Participant Enrollment Process 10:03 Participant Experience and Support 12:51 Join the Community! 13:40 Study Duration and Data Analysis 16:44 Dosing Strategies and Safety Considerations 22:17 Personal Journey with Long COVID 30:58 Decentralized Study Design and Accessibility 36:26 How to Enroll 38:16 Outro